|
enttäuschende Studiendaten von NKTR-214
www.marketwatch.com/story/...ing-cancer-trial-data-2018-06-04
die Suche nach dem Boden
www.fool.com/investing/2018/06/06/...umped-as-much-as-17.aspx
www.bloomberg.com/news/articles/...lp-set-a-brent-crude-price
www.thestreet.com/investing/stocks/...t-got-hammered-14610395
www.barrons.com/articles/...slumping-nektar-shares-1528743495
Short Attacke auf Nektar Therapeutics
www.fiercebiotech.com/biotech/...as-zero-value-claims-analyst
"Ich habe Rücken! Auch Horst Schlämmer ist betroffen!
Donnerstag, 29. August PDUFA
A study published in the American Pain Society's The Journal of Pain in October 2014 estimated that 19 percent of the U.S. population, or 39 million people, suffer from persistent pain.
In July 2018, the U.S. Food and Drug Administration filed and accepted a New Drug Application (NDA) for NKTR-181, a first-in-class opioid analgesic, to treat chronic low back pain in adult patients new to opioid therapy. In February 2019, Nektar received notification from the FDA that the review period for NKTR-181 has been extended by three months.....The FDA extended the action date to allow time to review data from two additional preclinical studies that Nektar conducted which were requested by the FDA early on in our review process. The new preclinical data are supportive of the company's abuse liability package included in the NDA filing for NKTR-181.https://ir.nektar.com/node/18031/html
NKTR-181 is the first long-acting, selective mu-opioid agonist designed to provide potent pain relief without the inherent high levels of euphoria which lead to abuse and addiction with standard opioids. https://www.nektar.com/pipeline/rd-pipeline/nktr-181
Pipeline: https://www.nektar.com/pipeline/rd-pipeline
The number of outstanding shares of Common Stock was 174,306,995 on May 1, 2019.
MK ca. 6 Mrd $
We estimate that we have working capital to fund our current business plans through at least the next twelve months. As of March 31, 2019, we had approximately $1.8 billion in cash and investments in marketable securities and had debt of $250.0 million in principal of senior secured notes due in October 2020.
Q1 2019 https://ir.nektar.com/node/18126/html
https://www.ariva.de/forum/...ine-2019-563893?new_pnr=26066757#bottom
FDA verschiebt PDUFA für NKTR-181 um etwa einen Monat
www.fiercebiotech.com/biotech/...onth-ahead-decision-deadline
endpts.com/...opioid-reviews-canceling-their-adcomm-showdown/
Führten Probleme im Qualitätsmanagement zu "schwachen" NKTR-214 Studiendaten?
markets.businessinsider.com/news/stocks/...-2019-8-1028434534
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 189 | Nektar Therap. - PEGylierung von Wirkstoffen = $$$ | Biotech4u | gdchs | 04.04.24 19:25 |